Research Priorities - Neuroscience
  • Article
  • Oct 9 2020

Butterfield is among the top 0.007% of scholars worldwide based on authorship of Alzheimer’s-related publications indexed in the PubMed database for the past 10 years. He ranks tenth out of nearly 150,000 scholars worldwide and sixth in the U.S.

  • Article
  • Sep 30 2020

In addition to opening the door to developing blockers of odors, McClintock says this work will help researchers understand why formulating fragrances and flavors with specific properties is so difficult. “Ergo, the oft-used phrase 'the art of perfumery.' Eventually, we will turn this art into science.”

  • Article
  • Sep 23 2020

Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.

  • Article
  • Aug 25 2020

Through the group's work, they found that the therapeutic targeting of TREM2 using a TREM2-activating antibody leads to the activation of microglia, recruitment of microglia to amyloid plaques, reduced amyloid deposition, and ultimately improved cognition.

  • Article
  • Aug 25 2020

“We used to think that aging-related memory and thinking decline meant one thing: a disease called Alzheimer’s disease. Now we know that the disease we were calling Alzheimer’s disease is actually many different conditions, often in combination."

  • Article
  • Aug 6 2020

Prendergast says statistics show that less than five percent of undergraduate neuroscience students in the U.S. are Black or African American, but at UK nearly ten percent of undergraduate neuroscience majors identify as Black or African American.

  • Article
  • Jul 30 2020

Researchers will be looking at a medication that recently received experimental approval from the USDA and its impact on the newly characterized form of dementia known as LATE. LATE is a disease with symptoms similar to Alzheimer’s disease.

  • Article
  • Jul 29 2020

For the past several decades, much of the work to find a treatment for AD has been focused on eliminating those dreaded Aβ plaques, by assuming that memory could be restored by removing the plaques.

  • Article
  • Jul 21 2020

The National Institutes of Health award will fund ongoing research led by UK Neuroscience and Spinal Cord and Brain Injury Research Center (SCoBIRC) Professor Patrick Sullivan, Ph.D., who has studied the effects of the experimental drug MP201 on TBI.

  • Article
  • Jul 17 2020

This work is looking at a study medication, BAN2401, to determine if it can help prevent worsening memory and thinking among individuals who might be at risk for future decline. They are hoping it will ultimately help prevent Alzheimer’s disease.